Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
23 hedge funds and large institutions have $4.46M invested in Seelos Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 5 closing their positions.
75% more capital invested
Capital invested by funds: $2.55M → $4.46M (+$1.92M)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
15% more funds holding
Funds holding: 20 → 23 (+3)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$259K |
| 2 |
BlackRock
New York
|
+$110K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$56.4K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$16.6K |
| 5 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
+$16.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
-$617K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$249K |
| 3 |
Renaissance Technologies
New York
|
-$86.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$16.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
SM
27
Sabby Management
Miami Beach,
Florida
| – | -$249K | -132 | Closed |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$17K | -9 | Closed |
|
|
TSS
29
Two Sigma Securities
New York
| – | -$14K | -7 | Closed |
|
30
Squarepoint
New York
| – | -$9K | -5 | Closed |
|
31
Victory Capital Management
San Antonio,
Texas
| – | -$6K | -4 | Closed |
|
SEEL Hedge Fund Activity: Q2 2020 in Review
23 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2020, worth a combined $4.46M — up 75% from $2.55M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SEEL positions and 5 closed out — a net gain of 3 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was CIBC World Market, opening a new position worth an estimated $259K. The largest seller was Uniplan Investment Counsel, cutting an estimated $617K.
- 23 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2020, up from 20 in Q1 2020.
- Funds reported $4.46M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2020, up 75% quarter-over-quarter.
- 8 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2020 and 5 closed out, a net change of +3 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2020 was CIBC World Market, an estimated $259K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2020 was Uniplan Investment Counsel, an estimated $617K sold.
Based on aggregated 13F filings for Q2 2020.